Efficacy and safety of Magnesium glycinate as Add on Therapy in Hypomagnesemic Asthma and Chronic Obstructive Pulmonary Disease Patients: A Randomised Controlled Study Assessing Inflammatory Biomarkers.

Authors

Maneesh Kumar Maddirevula, Muhasaparur G Rajanandh, Boman Wesley

Published in

Pulmonary pharmacology & therapeutics. Pages 102440. Aug 23, 2026. Epub Aug 23, 2026.

Abstract

Asthma and COPD are chronic respiratory conditions characterised by persistent airway inflammation, elevated inflammatory biomarkers (CRP, TNF-α, IL-6, IL-10), and frequent hypomagnesaemia, which worsens disease severity despite standard treatments. This study evaluates the efficacy and safety of Magnesium glycinate (440 mg/day) as add on therapy in the management of asthma and COPD. This randomised, double-blind, placebo-controlled trial enrolled 224 adults (112 Asthma and 112 COPD) with confirmed hypomagnesemia (Serum magnesium < 1.6 mg/dL) at Arogyavaram Medical Centre, India. Participants received oral magnesium glycinate 440 mg daily (n=112) or placebo (n=112) for 12 months alongside standard therapy. Primary outcomes were changes in CRP, TNF-α, IL-6, and IL-10. Secondary outcomes included FEV1/FVC ratio, serum magnesium, quality of life, medication adherence, and adverse drug reactions. Mixed-effects models and t-tests were used (P<0.05). Magnesium glycinate supplementation significantly reduced systemic inflammation and improved pulmonary function in both asthma and COPD patients compared with placebo, as demonstrated by reductions in CRP (asthma: -0.97 mg/L, 95% CI -1.34 to -0.61, P<0.001; COPD: -3.42 mg/L, 95% CI -4.23 to -2.61, P<0.001) and improvements in FEV₁ (asthma: +0.23 L, p=0.002; COPD: +0.19 L, p=0.004). Alongside an increase in the anti-inflammatory cytokine IL-10 (+2.8 pg/mL, 95% CI +0.61 to +4.99, p=0.013) and the intervention was well tolerated with no serious adverse events compared to placebo. Adjunctive magnesium glycinate safely reduces inflammatory biomarkers, particularly CRP, in hypomagnesemic asthma and COPD patients, with stronger cytokine modulation in COPD.

PMID:
42633850
Bibliographic data and abstract were imported from PubMed on 24 Aug 2026.

Read full publication at:
Please sign in to see all details.

Stats

1-terrible, 9-excellent. How would you rate this publication? Sign in in to submit your rating.

Post a comment

You need to be signed in to post comments. You can sign in here.

Comments

There are no comments yet.